Breast Cancer: Blocking both driver and escape pathways improves outcomes

Nat Rev Clin Oncol. 2012 Feb 14;9(3):133-4. doi: 10.1038/nrclinonc.2012.9.
No abstract available

Publication types

  • News

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Everolimus
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Receptor, ErbB-2 / drug effects
  • Receptors, Estrogen / antagonists & inhibitors*
  • Receptors, Estrogen / drug effects
  • Sirolimus / analogs & derivatives*
  • Sirolimus / therapeutic use
  • Women's Health

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Immunosuppressive Agents
  • Receptors, Estrogen
  • Everolimus
  • Receptor, ErbB-2
  • pertuzumab
  • Sirolimus